Latest News
Genentech’s Risdiplam Showed Significant Improvement in Motor Function in People Aged 2-25 Years with Type 2 or Type 3 SMA
Genentech, a member of the Roche Group, today presented 1-year data from the pivotal Part 2 of the SUNFISH study, evaluating risdiplam in people aged 2-25 years with Type 2 […]
Read More ›Cure SMA Adds New Equipment Item for Teens and Adults with SMA
Along with funding SMA research and offering clinical care services, Cure SMA provides thousands of affected individuals and families with vital support and resources that help them navigate daily life […]
Read More ›Summit of Strength Program Dates Confirmed
Cure SMA is happy to announce the schedule for the 2020 Summit of Strength Program! Currently entering its third year, we have brought together nearly 3,000 community members from across […]
Read More ›Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants with Type 1 SMA
Genentech, a member of the Roche Group, today announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type […]
Read More ›Annual SMA Conference Registration Continues to Grow!
The 2020 Annual SMA Conference registration numbers are growing quickly! We expect the 2020 conference – which includes both the Family Conference and the Research & Clinical Care Meeting – […]
Read More ›Community Statement from Scholar Rock Regarding SRK-015
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today highlighted key accomplishments of the past year […]
Read More ›